WO2009104900A2 - Composition comprising a flower extract of lonicera japonica thunb for preventing and treating arthritic diseases - Google Patents

Composition comprising a flower extract of lonicera japonica thunb for preventing and treating arthritic diseases Download PDF

Info

Publication number
WO2009104900A2
WO2009104900A2 PCT/KR2009/000771 KR2009000771W WO2009104900A2 WO 2009104900 A2 WO2009104900 A2 WO 2009104900A2 KR 2009000771 W KR2009000771 W KR 2009000771W WO 2009104900 A2 WO2009104900 A2 WO 2009104900A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
lonicera japonica
japonica thunb
present
flower extract
Prior art date
Application number
PCT/KR2009/000771
Other languages
French (fr)
Other versions
WO2009104900A3 (en
Inventor
Dong-Suk Park
Myung Chul Yoo
Do-Young Choi
Jae Dong Lee
Hyung In Yang
Yong-Hyeon Baek
Jeong-Eun Huh
Kyoung Soo Kim
Yong-Baik Cho
In Ho Jung
Jong Hyun Hur
Original Assignee
University-Industry Cooperation Group Of Kyung Hee University
Whan In Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University-Industry Cooperation Group Of Kyung Hee University, Whan In Pharmaceutical Company filed Critical University-Industry Cooperation Group Of Kyung Hee University
Publication of WO2009104900A2 publication Critical patent/WO2009104900A2/en
Publication of WO2009104900A3 publication Critical patent/WO2009104900A3/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Definitions

  • the present invention relates to a composition comprising a flower extract of Lonicera japonica THUNB for the prevention and treatment of arthritic disease.
  • Arthritis is an autoimmune disease characterized by their symptoms such as pain, swelling and stiffness in the joints.
  • the two major forms of arthritis in mammals are inflammatory arthritis such as rheumatoid arthritis (RA), and osteoarthritis (OA), a progressive, degenerative loss of cartilage often secondary to mechanical stress, aging, dysplastic conditions and/or injury.
  • the symptoms of arthritis generally relates to arthrosis of spine, e.g., hallux rigidus, arthrosis psoriaticum, or rheumatic arthritis.
  • Osteoarthritis manifests similar symptoms to a rheumatoid arthritis (RA).
  • RA rheumatoid arthritis
  • cartilage deteriorates, a reactive synovitis often develops later on.
  • rheumatoid arthritis erodes cartilage, the secondary osteoarthritis changes the bone and cartilage development.
  • the joints suffering with both diseases appear the same phenomena with each other.
  • Osteoarthritis usually represents a pain which become worsen with exercise or a simple X-ray radiation showing clearly a thinned cartilage.
  • Commonly affected joints are knees, hips, spine, finger, base of thumb or big toe etc.
  • MMPs matrix metaloproteinases
  • the disease is involved in the destruction of articular cartilage by MMPs (matrix metaloproteinases) which mainly works for cartilage depletion, which is characterized by degenerative changes in the articular cartilage and caused by the over-production of inflammatory cytokines, e.g., interleukin-1 (IL-1), tumor necrosis factor-a (TNF-a) etc, causing to extremely severe pain in joints, tendons, muscles and ligament (Fernandes J.C., The role of cytokines in osteoarthritis pathophysiology , 39 , pp237-246, 2002).
  • IL-1 interleukin-1
  • TNF-a tumor necrosis factor-a
  • Rheumatoid arthritis is a common autoimmune disease characterized by the swelling, deformation and destruction of joint, which culminates in severe physical disability.
  • Rheumatic diseases include the diseases occurring at muscles, tendons, joints, bones or sinus, which are generally characterized by an inflammation and/or degeneration.
  • the patients suffering with rheumatoid arthritis present the imbalance in immune system, which causes an overproduction of pro-inflammatory cytokines, e.g., TNF-a, IL-1 etc, and a lack of anti-inflammatory cytokines, e.g., IL-10, IL-1, etc.
  • RA is characterized by synovial inflammation, which progresses to a cartilage destruction, bone erosion and subsequent joint deformity.
  • polymorphonuclear cells, macrophages and lymphocytes are released from the joint.
  • Activated T-lymphocytes produce cytotoxins and pro-inflammatory cytokines, while macrophages stimulate the release of the prostaglandins and cytotoxins.
  • Vasoactive substances such as histamine, kinins and prostaglandins, are released at the site of inflammation and they cause to an edema, erythema and pain at the region of the inflamed joints.
  • the main pathology of the affected synovial tissue is a hyperplasia and the sub-intimal infiltration of T and B lymphocytes.
  • Synovial tissue hyperplasia forms in pannus tissue, which irreversibly destroys the cartilage and bone in the affected joint.
  • RA progression is associated with elevated levels of TNF-a and IL-1b produced by macrophages and dendrite cells, an imbalance of Th1/Th2 and over-production of antigen specific immunoglobulins.
  • TNF-a and IL-1b directly induce the synthesis of proteolytic enzyme such as matrix metalloproteinase (MMPs) which can break down the extracellular matrix macromolecules.
  • MMPs matrix metalloproteinase
  • TIMPs tissue inhibitors of metalloproteinases
  • the first aid drugs for treating arthritis includes the drug for alleviating pain and inflammation, which is classified into non-steroidal anti-inflammatory drugs (NSAIDs), e.g., aspirin, ibuprofen, naproxen, methotrexate, etc.
  • Secondary aid drugs include corticosteroids, slow acting antirheumatic drugs (SAARDs) or disease modifying drugs (DMs), e.g., penicilamine, cyclophosphamide, gold salts, azethioprine, levamisole, etc.
  • SAARDs slow acting antirheumatic drugs
  • DMs disease modifying drugs
  • BRMs biological-response modifiers
  • TNF-a antagonists which plays role in binding to its receptor or directly binding to the TNF-a protein.
  • the use of DMARDs has been impeded by various disadvantages, for example, the potential of its long-term side effects and toxicity, high cost, hypersensitivity to the medications and infections due to TNF-a blockage, etc
  • Degenerative arthritis one of representative osteo-joint diseases is chronic arthritis. It is difficult to treat the disease with conventionally available anti-inflammatory drugs in clinic. Moreover, the drugs give rise to systemic adverse response such as digestive disorder, gastro-intestinal disorder and renal function disorder and the adverse response of the drugs occurs more frequently as the age of patient increases, which causes lots of problems in case of long-term systemic treatment in older people. Therefore, the new drug development targeting anti-inflammatory effect, protecting and regenerating effect on cartilage has been urgently needed than previous systemic treatment therapy recently.
  • Lonicerae Japonicae is a flower bud part of Lonicerae spp. belonged to Caprifoliaceae. They have been conventionally used to treat or prevent bacterial infection and known to contain luteolin, inositol, saponin, tannin, isochlorogenic acid, chlorogenic acid etc as main components (B.S. Chung et al., HyangYakDaeSaJeon, Youngrimsa, pp939-940, 1989).
  • the present inventors have confirmed that the flower extract of Lonicera japonica THUNB shows potent analgesic activity, anti-inflammatory activity and anti-rheumatic activity through various experiments, i.e., the analgesic activity proved by formalin analgesic test, radiation-induced tail flick analgesia test, and rat-paw pressure analgesia test; anti-inflammatory activity proved by croton-oil induced ear oedema test; and anti-rheumatic activity proved by MIA-induced arthritis animal model test, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.
  • the present invention provides a composition comprising a flower extract of Lonicera japonica THUNB for the prevention and treatment of arthritic disease.
  • a pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB as an active ingredient for preventing and treating of arthritic disease.
  • extract includes: the crude extract soluble in water, C 1 to C 4 lower alcohol and the mixture thereof, preferably, the mixture of water and ethanol, more preferably, 30 ⁇ 70% ethanol solution; the purified extract by fractionating the crude extract to collect butanol soluble extract containing abundant chlorogenic acid, most preferably, the extract containing chlorogenic acid, preferably, 1.5 ⁇ 4.0 (w/w%) chlorogenic acid as a standard component in total extract.
  • arthritis disease includes degenerative arthritis, rheumatic arthritis or Lupus arthritis, preferably, rheumatic arthritis.
  • the present invention also provided a use of a flower extract of Lonicera japonica THUNB for the preparation of therapeutic agent for the treatment and prevention of arthritic disease in mammal or human.
  • the present invention also provided a pharmaceutical composition
  • a pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB as an active ingredient and a pharmaceutically acceptable carrier thereof for treating and preventing arthritic disease.
  • An inventive extract of the present invention can be prepared in detail by following procedures.
  • Lonicera japonica THUNB is dried, cut, crushed to 1 to 20-fold, preferably, approximately 5 to 10-fold volume of distilled water, C 1 to C 4 lower alcohols or the mixtures thereof, preferably the mixture of water and ethanol with approximately 1: 0.1 to 1: 10, more preferably, 1: 0.5 to 1:5 (v/v); the solution is performed to extraction at the temperature ranging from 10°C ⁇ 100°C, preferably, 60°C ⁇ 100°C, for the period ranging from 1 to 6 hours, preferably, 2 to 4 hours with the extraction method by the extraction with hot water, cold water, reflux extraction, or ultra-sonication extraction, preferably, extraction with hot water; the extract is collected with filtration, concentrated under reduced pressure and dried to obtain an inventive crude extract of the present invention.
  • inventive purified extract of the present invention the crude extract prepared by the above-described method is fractionated with equal volume of saturated butanol to collect inventive butanol soluble extract of the present invention.
  • the present invention also provided a use of a flower extract of Lonicera japonica THUNB prepared by the above-described preparation method for the preparation of therapeutic agent for the treatment and prevention of arthritic disease in mammal or human.
  • the present invention also provided a pharmaceutical composition
  • a pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB prepared by the above-described preparation method as an active ingredient and a pharmaceutically acceptable carrier thereof for treating and preventing arthritic disease.
  • the inventive extract of the present invention prepared by above-described method shows potent analgesic activity, anti-inflammatory activity and anti-rheumatic activity through various experiments, i.e., the analgesic activity proved by formalin analgesic test, radiation-induced tail flick analgesia test, and rat-paw pressure analgesia test; anti-inflammatory activity proved by croton-oil induced ear oedema test; and anti-rheumatic activity proved by MIA-induced arthritis animal model test.
  • the inventive composition for treating and preventing arthritic diseases may comprises the above-described extract as 0.1 ⁇ 50% by weight based on the total weight of the composition.
  • the inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington s Pharmaceutical Science (Mack Publishing co, Easton PA).
  • composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • pharmaceutically acceptable carriers e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl
  • the formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
  • compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the extract of the present invention can be formulated in the form of ointments and creams.
  • compositions containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
  • oral dosage form prowder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule
  • topical preparation cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like
  • injectable preparation solution, suspension, emulsion
  • composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.1 to 1000 mg/kg, preferably, 1 to 100 mg/kg by weight/day of the inventive extract of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably 0.5 to 40% by weight based on the total weight of the composition.
  • composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intra-cutaneous, intrathecal, epidural or intra-cerebroventricular injection.
  • a functional health food comprising a flower extract of Lonicera japonica THUNB as an active ingredient.
  • a functional health food defined herein is “the functional food having enhanced functionality such as physical functionality or physiological functionality by adding the extract of the present invention to conventional food to prevent or improve aimed disease in human or mammal”.
  • a health care food defined herein is “the food containing inventive extract of the present invention showing no specific intended effect but general intended effect in a small amount of quantity as a form of additive or in a whole amount of quantity as a form of capsule, pill, tablet etc”.
  • a sitologically acceptable additive defined herein is “any substance the intended use which results or may reasonably be expected to result-directly or indirectly-in its becoming a component or otherwise affecting the characteristics of any food”for example, thickening agent, maturing agent, bleaching agent, sequesterants, humectant, anticaking agent, clarifying agents, curing agent, emulsifier, stabilizer, thickner, bases and acid, foaming agents, nutrients, coloring agent, flavoring agent, sweetner, preservative agent, antioxidant, etc, which had been well-known in the art.
  • direct additive a substance that becomes part of the food in trace amounts due to its packaging, storage or other handling.
  • Health foods can be contained in food, health beverage, dietary therapy etc, and may be used as a form of powder, granule, tablet, chewing tablet, capsule, beverage etc for preventing or improving aimed disease.
  • inventive extract can be added to food or beverage for prevention and improvement of aimed disease.
  • the amount of inventive extract in food or beverage as a functional health food or health care food may generally range from about 0.01 to 100 w/w % of total weight of food for functional health food composition.
  • the preferable amount of inventive extract of the present invention in the functional health food, health care food or special nutrient food may be varied in accordance to the intended purpose of each food, it is preferably used in general to use as a additive in the amount of inventive extract of the present invention ranging from about 0.01 to 5% in food such as noodles and the like, from 40 to 100% in health care food on the ratio of 100% of the food composition.
  • the health beverage composition of present invention contains inventive extract as an essential component in the indicated ratio
  • the other component can be various deodorant or natural carbohydrate etc such as conventional beverage.
  • natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cyclodextrin; and sugar alcohol such as xylitol, and erythritol etc.
  • natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al.
  • the amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably 5 to 12 g in the ratio of 100 ml of present beverage composition.
  • the other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese, chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al.
  • the other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination.
  • the ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition.
  • Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health improving food and the like.
  • the present invention comprising a flower extract of Lonicera japonica THUNB shows potent analgesic activity, anti-inflammatory activity and anti-rheumatic activity through various experiments, i.e., the analgesic activity proved by formalin analgesic test, radiation-induced tail flick analgesia test, and rat-paw pressure analgesia test; anti-inflammatory activity proved by croton-oil induced ear oedema test; and anti-rheumatic activity proved by MIA-induced arthritis animal model test, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.
  • Fig. 1 shows the result of chromatogram analysis on the content of chlorogenic acid, a standard component contained in the flower extract of Lonicera japonica THUNB;
  • the GA50E extract contains 2.2% chlorogenic acid (w/w%) through chromatogram analysis ( See , Fig. 1).
  • the GB50E extract contains 3.0% chlorogenic acid (w/w%) through chromatogram analysis.
  • mice Male ICR mouse (Orient Bio, Japan) weighing from 20 to 25 g was acclimated for several days and each group consists of 8 mice. The test samples were administrated orally into the mice and 10 % formalin solution (v/v Sigma Co. USA) was subcutaneously administrated to the left posterior limb one hour after the administration. The licking frequency of the foot sole was observed at the 1 st phase (from initial time to 5 minutes after the administration) and 2 nd phase (from 15 minutes to 20 minutes after the administration) to record. The inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
  • Celecoxib a conventionally used NSAID
  • MIA monosodium iodoactetate
  • mice Male SD rat (Orientbio. Japan) weighing from 200 to 220 g, was acclimated for several days and MIA (Sigma, cat# I2512, USA) dissolved in PBS was injected into the glenoid cavity of left hind knee to induce arthritis. After a week of recovery, the subjects induced with arthritis were selected by using incapacitance tester apparatus (Linton, Stoelting Co., Wood Dale, IL) and the subjects were grouped to consist of 8 animals for each group. On the 8 th day after the induction, the test samples were orally administered at the routine time for every day and the measurement of resulting data was started at one week after the administration for 3 weeks, once a week.
  • MIA Sigma, cat# I2512, USA
  • the data was measured using by incapacitance tester (Linton, Stoelting Co., Wood Dale, IL) and calculated according to following Math figure 1.
  • the inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
  • rat paw pressure analgesia test was performed with the procedure described in the literature (Randall LO and Selitto JJ, Arch Int. Pharmacodyn ., 111 , pp409-419, 1957).
  • Croton oil induces various skin inflammations such as rash, swelling, blister and so on.
  • mice Male ICR mouse (Orientbio. Japan)) weighing from 20 to 25g was used as an experimental animal and each group consists of 6 mice. The test samples were administrated orally and after 1 hour, 2.5% croton oil dissolved in acetone was spread on the inner and outer surface of right ear to induce ear-edema. After 4 hours, the increased rate of ear thickness was calculated by comparing with that of left ear of dead mouse with ether using by thickness gauge according to velocity transformation technique (Patrick et al., Toxicol. Appl. Pharmacol. , 81 , pp476-490, 1985).
  • the inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
  • Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2 ml ample and sterilizing by conventional injection preparation method.
  • Powder preparation was prepared by mixing above components and filling sealed package.
  • Tablet preparation was prepared by mixing above components and entabletting.
  • Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.
  • Liquid preparation was prepared by dissolving active component, and then filling all the components in 1000ml ample and sterilizing by conventional liquid preparation method.
  • Vitamin A acetate 70mg
  • Vitamin E 1.0mg
  • Vitamin B 1 0.13mg
  • Vitamin B6 0.5mg
  • Vitamin B12 0.2 ⁇ g
  • Health beverage preparation was prepared by dissolving active component, mixing, stirred at 85°C for 1 hour, filtered and then filling all the components in 1000ml ample and sterilizing by conventional health beverage preparation method.
  • the inventive compositions comprising the extract of Lonicera japonica THUNB shows potent anti-inflammatory effect through various experiments, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is related to the inventive compositions comprising the extract of Lonicera japonica THUNB showing potent anti-inflammatory activity, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.

Description

COMPOSITION COMPRISING A FLOWER EXTRACT OF LONICERA JAPONICA THUNB FOR PREVENTING AND TREATING ARTHRITIC DISEASES
The present invention relates to a composition comprising a flower extract of Lonicera japonica THUNB for the prevention and treatment of arthritic disease.
Arthritis is an autoimmune disease characterized by their symptoms such as pain, swelling and stiffness in the joints. The two major forms of arthritis in mammals are inflammatory arthritis such as rheumatoid arthritis (RA), and osteoarthritis (OA), a progressive, degenerative loss of cartilage often secondary to mechanical stress, aging, dysplastic conditions and/or injury. The symptoms of arthritis generally relates to arthrosis of spine, e.g., hallux rigidus, arthrosis psoriaticum, or rheumatic arthritis.
Osteoarthritis manifests similar symptoms to a rheumatoid arthritis (RA). In particular, although osteoarthritis begins as a degeneration of articular cartilage, RA begins as an inflammation in synovium. In osteoarthritis, as cartilage deteriorates, a reactive synovitis often develops later on. Conversely, as rheumatoid arthritis erodes cartilage, the secondary osteoarthritis changes the bone and cartilage development. At the final stages of both osteoarthritis and rheumatoid arthritis, the joints suffering with both diseases appear the same phenomena with each other.
Osteoarthritis usually represents a pain which become worsen with exercise or a simple X-ray radiation showing clearly a thinned cartilage. Commonly affected joints are knees, hips, spine, finger, base of thumb or big toe etc. The disease is involved in the destruction of articular cartilage by MMPs (matrix metaloproteinases) which mainly works for cartilage depletion, which is characterized by degenerative changes in the articular cartilage and caused by the over-production of inflammatory cytokines, e.g., interleukin-1 (IL-1), tumor necrosis factor-a (TNF-a) etc, causing to extremely severe pain in joints, tendons, muscles and ligament (Fernandes J.C., The role of cytokines in osteoarthritis pathophysiology, 39, pp237-246, 2002). Rheumatoid arthritis (RA) is a common autoimmune disease characterized by the swelling, deformation and destruction of joint, which culminates in severe physical disability. Rheumatic diseases include the diseases occurring at muscles, tendons, joints, bones or sinus, which are generally characterized by an inflammation and/or degeneration. The patients suffering with rheumatoid arthritis present the imbalance in immune system, which causes an overproduction of pro-inflammatory cytokines, e.g., TNF-a, IL-1 etc, and a lack of anti-inflammatory cytokines, e.g., IL-10, IL-1, etc. RA is characterized by synovial inflammation, which progresses to a cartilage destruction, bone erosion and subsequent joint deformity. During the inflammation process, polymorphonuclear cells, macrophages and lymphocytes are released from the joint. Activated T-lymphocytes produce cytotoxins and pro-inflammatory cytokines, while macrophages stimulate the release of the prostaglandins and cytotoxins. Vasoactive substances such as histamine, kinins and prostaglandins, are released at the site of inflammation and they cause to an edema, erythema and pain at the region of the inflamed joints.
The main pathology of the affected synovial tissue is a hyperplasia and the sub-intimal infiltration of T and B lymphocytes. Synovial tissue hyperplasia forms in pannus tissue, which irreversibly destroys the cartilage and bone in the affected joint. RA progression is associated with elevated levels of TNF-a and IL-1b produced by macrophages and dendrite cells, an imbalance of Th1/Th2 and over-production of antigen specific immunoglobulins. Especially, TNF-a and IL-1b directly induce the synthesis of proteolytic enzyme such as matrix metalloproteinase (MMPs) which can break down the extracellular matrix macromolecules. Under normal condition, the tissue inhibitors of metalloproteinases (TIMPs) normally bind to MMPs with the ratio of 1:1. The imbalanced ratio of TIMPs to MMPs which is generally caused by the up-regulation of MMPs, results in the continued matrix destruction in RA.
The first aid drugs for treating arthritis includes the drug for alleviating pain and inflammation, which is classified into non-steroidal anti-inflammatory drugs (NSAIDs), e.g., aspirin, ibuprofen, naproxen, methotrexate, etc. Secondary aid drugs include corticosteroids, slow acting antirheumatic drugs (SAARDs) or disease modifying drugs (DMs), e.g., penicilamine, cyclophosphamide, gold salts, azethioprine, levamisole, etc. The first groups of biological-response modifiers (BRMs) approved by FDA for treatment of RA are TNF-a antagonists which plays role in binding to its receptor or directly binding to the TNF-a protein. However, the use of DMARDs has been impeded by various disadvantages, for example, the potential of its long-term side effects and toxicity, high cost, hypersensitivity to the medications and infections due to TNF-a blockage, etc.
Degenerative arthritis, one of representative osteo-joint diseases is chronic arthritis. It is difficult to treat the disease with conventionally available anti-inflammatory drugs in clinic. Moreover, the drugs give rise to systemic adverse response such as digestive disorder, gastro-intestinal disorder and renal function disorder and the adverse response of the drugs occurs more frequently as the age of patient increases, which causes lots of problems in case of long-term systemic treatment in older people. Therefore, the new drug development targeting anti-inflammatory effect, protecting and regenerating effect on cartilage has been urgently needed than previous systemic treatment therapy recently. The recent theory of drug development has been focused on joint tissue lyase inhibitor, free radical scavenger such as SOD, conservation therapy using by long-term treatment of joint tissue components such as chondroitin or glucosamine etc (Badger A. M. et al., J. Pharmacol. Exp. Ther., 290, pp587-593, 1999; Choi J.H. et al., Osteoarthritis Cartilage, 10(6), pp471-478, 2002).
Lonicerae Japonicae is a flower bud part of Lonicerae spp. belonged to Caprifoliaceae. They have been conventionally used to treat or prevent bacterial infection and known to contain luteolin, inositol, saponin, tannin, isochlorogenic acid, chlorogenic acid etc as main components (B.S. Chung et al., HyangYakDaeSaJeon, Youngrimsa, pp939-940, 1989).
However, there has been not reported or disclosed about the therapeutic effect of a flower extract of Lonicera japonica THUNB on the arthritic disease in any of above cited literatures, the disclosures of which are incorporated herein by reference.
Accordingly, the present inventors have confirmed that the flower extract of Lonicera japonica THUNB shows potent analgesic activity, anti-inflammatory activity and anti-rheumatic activity through various experiments, i.e., the analgesic activity proved by formalin analgesic test, radiation-induced tail flick analgesia test, and rat-paw pressure analgesia test; anti-inflammatory activity proved by croton-oil induced ear oedema test; and anti-rheumatic activity proved by MIA-induced arthritis animal model test, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.
According to one aspect of the present invention, the present invention provides a composition comprising a flower extract of Lonicera japonica THUNB for the prevention and treatment of arthritic disease.
Accordingly, it is an object of the present invention to provide a pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB as an active ingredient for preventing and treating of arthritic disease.
The term “extract”disclosed herein includes: the crude extract soluble in water, C1 to C4 lower alcohol and the mixture thereof, preferably, the mixture of water and ethanol, more preferably, 30∼70% ethanol solution; the purified extract by fractionating the crude extract to collect butanol soluble extract containing abundant chlorogenic acid, most preferably, the extract containing chlorogenic acid, preferably, 1.5∼4.0 (w/w%) chlorogenic acid as a standard component in total extract.
The term “arthritic disease”disclosed herein includes degenerative arthritis, rheumatic arthritis or Lupus arthritis, preferably, rheumatic arthritis.
The present invention also provided a use of a flower extract of Lonicera japonica THUNB for the preparation of therapeutic agent for the treatment and prevention of arthritic disease in mammal or human.
The present invention also provided a pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB as an active ingredient and a pharmaceutically acceptable carrier thereof for treating and preventing arthritic disease.
It is an object of the present invention to provide a method of treating or preventing cancer disease in human or mammal, wherein the method comprises administering a therapeutically effective amount of a flower extract of Lonicera japonica THUNB, as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
Hereinafter, the present invention is described in detail.
An inventive extract of the present invention can be prepared in detail by following procedures.
For example, Lonicera japonica THUNB is dried, cut, crushed to 1 to 20-fold, preferably, approximately 5 to 10-fold volume of distilled water, C1 to C4 lower alcohols or the mixtures thereof, preferably the mixture of water and ethanol with approximately 1: 0.1 to 1: 10, more preferably, 1: 0.5 to 1:5 (v/v); the solution is performed to extraction at the temperature ranging from 10℃∼100℃, preferably, 60℃∼100℃, for the period ranging from 1 to 6 hours, preferably, 2 to 4 hours with the extraction method by the extraction with hot water, cold water, reflux extraction, or ultra-sonication extraction, preferably, extraction with hot water; the extract is collected with filtration, concentrated under reduced pressure and dried to obtain an inventive crude extract of the present invention.
To obtain inventive purified extract of the present invention, the crude extract prepared by the above-described method is fractionated with equal volume of saturated butanol to collect inventive butanol soluble extract of the present invention.
Also, the above-described procedures may be modified or subjected to further step to fractionate or isolate more potent fractions or compounds by conventional procedure well- known in the art, for example, the procedure disclosed in the literature (Harborne J. B. Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. pp6-7, 1998).
Accordingly, the present invention also provided a use of a flower extract of Lonicera japonica THUNB prepared by the above-described preparation method for the preparation of therapeutic agent for the treatment and prevention of arthritic disease in mammal or human.
The present invention also provided a pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB prepared by the above-described preparation method as an active ingredient and a pharmaceutically acceptable carrier thereof for treating and preventing arthritic disease.
It is an object of the present invention to provide a method of treating or preventing cancer disease in human or mammal, wherein the method comprises administering a therapeutically effective amount of a flower extract of Lonicera japonica THUNB prepared by the above-described preparation method, as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
It is confirmed that the inventive extract of the present invention prepared by above-described method shows potent analgesic activity, anti-inflammatory activity and anti-rheumatic activity through various experiments, i.e., the analgesic activity proved by formalin analgesic test, radiation-induced tail flick analgesia test, and rat-paw pressure analgesia test; anti-inflammatory activity proved by croton-oil induced ear oedema test; and anti-rheumatic activity proved by MIA-induced arthritis animal model test.
The inventive composition for treating and preventing arthritic diseases may comprises the above-described extract as 0.1 ~ 50% by weight based on the total weight of the composition.
The inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington s Pharmaceutical Science (Mack Publishing co, Easton PA).
Hereinafter, the following formulation methods and excipients are merely exemplary and in no way limit the invention.
The composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
For example, the compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them. For topical administration, the extract of the present invention can be formulated in the form of ointments and creams.
Pharmaceutical formulations containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
The composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
The desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.1 to 1000 mg/kg, preferably, 1 to 100 mg/kg by weight/day of the inventive extract of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably 0.5 to 40% by weight based on the total weight of the composition.
The pharmaceutical composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intra-cutaneous, intrathecal, epidural or intra-cerebroventricular injection.
Accordingly, it is the other object of the present invention to provide a functional health food comprising a flower extract of Lonicera japonica THUNB as an active ingredient.
The term “a functional health food” defined herein is “the functional food having enhanced functionality such as physical functionality or physiological functionality by adding the extract of the present invention to conventional food to prevent or improve aimed disease in human or mammal”.
It is the other object of the present invention to provide a health care food comprising a flower extract of Lonicera japonica THUNB, together with a sitologically acceptable additive for the prevention and alleviation of aimed disease.
The term “a health care food”defined herein is “the food containing inventive extract of the present invention showing no specific intended effect but general intended effect in a small amount of quantity as a form of additive or in a whole amount of quantity as a form of capsule, pill, tablet etc”.
The term “a sitologically acceptable additive”defined herein is “any substance the intended use which results or may reasonably be expected to result-directly or indirectly-in its becoming a component or otherwise affecting the characteristics of any food”for example, thickening agent, maturing agent, bleaching agent, sequesterants, humectant, anticaking agent, clarifying agents, curing agent, emulsifier, stabilizer, thickner, bases and acid, foaming agents, nutrients, coloring agent, flavoring agent, sweetner, preservative agent, antioxidant, etc, which had been well-known in the art.
If a substance is added to a food for a specific purpose in that food, it is referred to as a direct additive and indirect food additives are those that become part of the food in trace amounts due to its packaging, storage or other handling.
Above described health foods can be contained in food, health beverage, dietary therapy etc, and may be used as a form of powder, granule, tablet, chewing tablet, capsule, beverage etc for preventing or improving aimed disease.
Also, inventive extract can be added to food or beverage for prevention and improvement of aimed disease. The amount of inventive extract in food or beverage as a functional health food or health care food may generally range from about 0.01 to 100 w/w % of total weight of food for functional health food composition. In particular, although the preferable amount of inventive extract of the present invention in the functional health food, health care food or special nutrient food may be varied in accordance to the intended purpose of each food, it is preferably used in general to use as a additive in the amount of inventive extract of the present invention ranging from about 0.01 to 5% in food such as noodles and the like, from 40 to 100% in health care food on the ratio of 100% of the food composition.
Providing that the health beverage composition of present invention contains inventive extract as an essential component in the indicated ratio, there is no particular limitation on the other liquid component, wherein the other component can be various deodorant or natural carbohydrate etc such as conventional beverage. Examples of aforementioned natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cyclodextrin; and sugar alcohol such as xylitol, and erythritol etc. As the other deodorant than aforementioned ones, natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al., may be useful favorably. The amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably 5 to 12 g in the ratio of 100 ㎖ of present beverage composition.
The other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese, chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al. The other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination. The ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition. Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health improving food and the like.
It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions, use and preparations of the present invention without departing from the spirit or scope of the invention.
The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.
It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions, use and preparations of the present invention without departing from the spirit or scope of the invention.
The present invention comprising a flower extract of Lonicera japonica THUNB shows potent analgesic activity, anti-inflammatory activity and anti-rheumatic activity through various experiments, i.e., the analgesic activity proved by formalin analgesic test, radiation-induced tail flick analgesia test, and rat-paw pressure analgesia test; anti-inflammatory activity proved by croton-oil induced ear oedema test; and anti-rheumatic activity proved by MIA-induced arthritis animal model test, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.
The present invention is more specifically explained by the following figures and examples. However, it should be understood that the present invention is not limited to these examples in any manner.
The above and other objects, features and other advantages of the present invention will more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which;
Fig. 1 shows the result of chromatogram analysis on the content of chlorogenic acid, a standard component contained in the flower extract of Lonicera japonica THUNB;
It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions, use and preparations of the present invention without departing from the spirit or scope of the invention.
The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.
Mode for Invention
The following, Examples and Experimental Examples are intended to further illustrate the present invention without limiting its scope.
Example 1. Preparation of Lonicera japonica THUNB extract (GA50E).
100 g of Lonicera japonica THUNB purchased from Kyunghee Medical Center in Korea, was dried, cut into small pieces and added to 0.7 L of 50% ethanol. The solution was refluxed for 4 hours with stirring at 80℃ and the residue was filtered. The filtrate was concentrated to the extent that the volume of solution reached to 0.1 L and the equal volume of saturated butanol was added thereto to perform fractionation. the butanol soluble fraction was collected, concentrated and dried to obtain 7 g of the extract of herb, which was used as a test sample (designated as ‘GA50E extract ’hereinafter).
As shown in Fig. 1, it has been confirmed that the GA50E extract contains 2.2% chlorogenic acid (w/w%) through chromatogram analysis ( See , Fig. 1).
Example 2. Preparation of Lonicera japonica THUNB extract (GB50E).
100 g of Lonicera japonica THUNB purchased from Kyunghee Medical Center in Korea, was dried, cut into small pieces and added to 0.7 L of 50% ethanol. The solution was refluxed for 4 hours with stirring at 80℃ and the residue was filtered. The filtrate was concentrated and dried to obtain 40 g of the extract of herb, which was used as a test sample (designated as ‘GB50E extract ’ereinafter).
it has been confirmed that the GB50E extract contains 3.0% chlorogenic acid (w/w%) through chromatogram analysis.
Experimental Example 1. Formalin analgesia test
In order to determine the analgesic activity of the inventive extract of the present invention, formalin-induced analgesia test was performed according to the method disclosed in the literature as follows (Frazli-Tabaei S et al., Behav. Pharmacol. , 16, pp613-619, 2005).
Male ICR mouse (Orient Bio, Japan) weighing from 20 to 25 g was acclimated for several days and each group consists of 8 mice. The test samples were administrated orally into the mice and 10 % formalin solution (v/v Sigma Co. USA) was subcutaneously administrated to the left posterior limb one hour after the administration. The licking frequency of the foot sole was observed at the 1st phase (from initial time to 5 minutes after the administration) and 2nd phase (from 15 minutes to 20 minutes after the administration) to record. The inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
Table 1
Group Concentration (mg/kg) Inhibition rate (%)＊
1st phase 2nd phase
GA50E (Example 1) 400 110 70.0
GB50E (Example 2) 400 115 78.0
* Relative inhibition rate by setting the inhibition rate in positive control group treated with Celecoxib to 100
As shown in Table 1, it has been confirmed that both of GA50E and GB50E showed potent analgesic effect.
Experimental Example 2. MIA (Monosodium Iodoacetate) model
In order to confirm the analgesic activity of inventive extract prepared in Examples, MIA (monosodium iodoactetate)-induced arthritis animal model test was performed with the procedure described in the literature (James D. Pomonis et al., Pain, 114, pp339-346, 2005).
Male SD rat (Orientbio. Japan) weighing from 200 to 220 g, was acclimated for several days and MIA (Sigma, cat# I2512, USA) dissolved in PBS was injected into the glenoid cavity of left hind knee to induce arthritis. After a week of recovery, the subjects induced with arthritis were selected by using incapacitance tester apparatus (Linton, Stoelting Co., Wood Dale, IL) and the subjects were grouped to consist of 8 animals for each group. On the 8th day after the induction, the test samples were orally administered at the routine time for every day and the measurement of resulting data was started at one week after the administration for 3 weeks, once a week. The data was measured using by incapacitance tester (Linton, Stoelting Co., Wood Dale, IL) and calculated according to following Math figure 1. The inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
MathFigure 1
Figure PCTKR2009000771-appb-M000001
Table 2
Group Concentration (mg/kg) Inhibition rate (%)＊(at 3rd week)
GA50E (Example 1) 400 72.0
GB50E (Example 2) 400 85.1
* Relative inhibition rate by setting the inhibition rate in positive control group treated with Celecoxib to 100
As shown in Table 2, it has been confirmed that both of GA50E and GB50E showed potent analgesic effect.
Experimental Example 3. Radiation-induced tail flick analgesia test
In order to confirm the analgesic effect of inventive extract prepared in Examples, radiation-induced tail flick analgesia test was performed with the procedure described in the literature (Shaw FZ et al., Brain Res., 911(2), pp105-115, 2001).
Male ICR mouse (Orientbio. Japan) weighing from 20 to 25 g was acclimated for several days and grouped to 8 animals for each group. Test samples were orally administrated thereto. One hour after the treatment, the medianus of tails was irradiated with infrared ray to determine the time until the avoidance response appeared. The inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib(Pfizer Inc.), a conventionally used NSAID, to 100.
Table 3
Group Concentration (mg/kg) Inhibition rate (%)＊
GA50E (Example 1) 400 95.9
GB50E (Example 2) 400 105.4
* Relative inhibition rate by setting the inhibition rate in positive control group treated with Celecoxib to 100
As shown in Table 3, it has been confirmed that both of GA50E and GB50E showed potent analgesic effect.
Experimental Example 4. Paw pressure analgesia test
In order to confirm the analgesic effect of inventive extract prepared in Examples, rat paw pressure analgesia test was performed with the procedure described in the literature (Randall LO and Selitto JJ, Arch Int. Pharmacodyn., 111, pp409-419, 1957).
Male SD rat (Orientbio. Japan) weighing from 180 to 200 g was acclimated for several days and grouped to 8 animals for each group. Test samples were orally administrated thereto. One hour after the treatment, 2% carrageenan (Sigma Co., USA) was subcutaneously injected into the sinistral ramus posterior of the rat. 3 hours after the injection, the weight at the time that avoidance response appeared, was measured by using analgesic meter (Ugobasile, Italy). The inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
Table 4
Group Concentration (mg/kg) Inhibition rate (%)＊
GA50E (Example 1) 400 82.5
GB50E (Example 2) 400 96.8
* Relative inhibition rate by setting the inhibition rate in positive control group treated with Celecoxib to 100
As shown in Table 4, it has been confirmed that both of GA50E and GB50E showed potent analgesic effect.
Experimental Example 5. Test with croton oil induced ear oedema
Croton oil induces various skin inflammations such as rash, swelling, blister and so on.
In order to determine the anti-inflammatory activity of inventive extract, following test using croton oil-induced ear edema was performed according to method disclosed in the literature literature (Gabor M, Mouse ear inflammation models and their pharmacological applications, Published by Akademiai Kiado, Budapest, pp 24-28, 2000).
Male ICR mouse (Orientbio. Japan)) weighing from 20 to 25g was used as an experimental animal and each group consists of 6 mice. The test samples were administrated orally and after 1 hour, 2.5% croton oil dissolved in acetone was spread on the inner and outer surface of right ear to induce ear-edema. After 4 hours, the increased rate of ear thickness was calculated by comparing with that of left ear of dead mouse with ether using by thickness gauge according to velocity transformation technique (Patrick et al., Toxicol. Appl. Pharmacol., 81, pp476-490, 1985).
The inhibition rate (%) was calculated by setting the inhibition rate in positive control group treated with Celecoxib, a conventionally used NSAID, to 100.
Table 5
Group Concentration (mg/kg) Inhibition rate (%)＊
GA50E (Example 1) 400 100.9
GB50E (Example 1) 400 110.2
* Relative inhibition rate by setting the inhibition rate in positive control group treated with Celecoxib to 100
As shown in Table 5, it has been confirmed that both of GA50E and GB50E showed potent anti-inflammatory effect.
Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. The representative preparation examples were described as follows.
Preparation of injection
GA50E 100mg
Sodim methabifulfite 3.0mg
Methyl paraben 0.8mg
Propyl paraben 0.1mg
Distilled water for injection optimum amount
Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2 ml ample and sterilizing by conventional injection preparation method.
Preparation of powder
GB50E 500mg
Corn Starch 100mg
Lactose 100mg
Talc 10mg
Powder preparation was prepared by mixing above components and filling sealed package.
Preparation of tablet
GA50E 200mg
Corn Starch 100mg
Lactose 100mg
Magnesium stearate optimum amount
Tablet preparation was prepared by mixing above components and entabletting.
Preparation of capsule
GB50E 100mg
Lactose 50mg
Corn starch 50mg
Talc 2mg
Magnesium stearate optimum amount
Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.
Preparation of liquid
GA50E 1000mg
Sugar 20g
Polysaccharide 20g
Lemon flavor 20g
Liquid preparation was prepared by dissolving active component, and then filling all the components in 1000㎖ ample and sterilizing by conventional liquid preparation method.
Preparation of health care food
GB50E 1000mg
Vitamin mixture optimum amount
Vitamin A acetate 70mg
Vitamin E 1.0mg
Vitamin B1 0.13mg
Vitamin B2 0.15mg
Vitamin B6 0.5mg
Vitamin B12 0.2㎍
Vitamin C 10mg
Biotin 10㎍
Amide nicotinic acid 1.7mg
Folic acid 50㎍
Calcium pantothenic acid 0.5mg
Mineral mixture optimum amount
Ferrous sulfate 1.75mg
Zinc oxide 0.82mg
Magnesium carbonate 25.3mg
Monopotassium phosphate 15mg
Dicalcium phosphate 55mg
Potassium citrate 90mg
Calcium carbonate 100mg
Magnesium chloride 24.8mg
The above mentioned vitamin and mineral mixture may be varied in may ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention.
Preparation of health beverage
GB50E 1000mg
Citric acid 1000mg
Oligosaccharide 100g
Apricot concentration 2g
Taurine 1g
Distilled water 900㎖
Health beverage preparation was prepared by dissolving active component, mixing, stirred at 85℃ for 1 hour, filtered and then filling all the components in 1000㎖ ample and sterilizing by conventional health beverage preparation method.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
As described in the present invention, the inventive compositions comprising the extract of Lonicera japonica THUNB shows potent anti-inflammatory effect through various experiments, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing arthritic disease.

Claims (8)

  1. A pharmaceutical composition comprising a flower extract of Lonicera japonica THUNB as an active ingredient for the treatment and prevention of arthritic diseases
  2. The pharmaceutical composition of claim 1, wherein said extract is the crude extract soluble in water, C1 to C4 lower alcohol and the mixture thereof, or the purified extract by fractionating the crude extract to collect butanol soluble extract containing abundant chlorogenic acid.
  3. The pharmaceutical composition of claim 1, wherein said extract contains 1.5∼4.0 (w/w%) chlorogenic acid as a standard component in total extract.
  4. The pharmaceutical composition of claim 1, wherein said arthritic disease is degenerative arthritis, rheumatic arthritis or Lupus arthritis.
  5. A use of a flower extract of Lonicera japonica THUNB for the preparation of therapeutic agent for the treatment and prevention of arthritic disease in mammal or human.
  6. A method of treating or preventing cancer disease in human or mammal, wherein the method comprises administering a therapeutically effective amount of a flower extract of Lonicera japonica THUNB, as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
  7. A health care food comprising a flower extract of Flos Lonicera japonica THUNB, together with a sitologically acceptable additive for the prevention and alleviation of arthritic diseases.
  8. The health care food of claim 7, wherein said health care food is provided as powder, granule, tablet, capsule or beverage type.
PCT/KR2009/000771 2008-02-19 2009-02-18 Composition comprising a flower extract of lonicera japonica thunb for preventing and treating arthritic diseases WO2009104900A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0014951 2008-02-19
KR1020080014951A KR101016837B1 (en) 2008-02-19 2008-02-19 Composition comprising the extract of Lonicera japonica THUNB. preventing and treating arthritis

Publications (2)

Publication Number Publication Date
WO2009104900A2 true WO2009104900A2 (en) 2009-08-27
WO2009104900A3 WO2009104900A3 (en) 2009-11-12

Family

ID=40986043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000771 WO2009104900A2 (en) 2008-02-19 2009-02-18 Composition comprising a flower extract of lonicera japonica thunb for preventing and treating arthritic diseases

Country Status (2)

Country Link
KR (1) KR101016837B1 (en)
WO (1) WO2009104900A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102648930A (en) * 2011-02-24 2012-08-29 北京灏銮科技发展有限公司 Microwave processing method for honeysuckle
CN102816066A (en) * 2012-08-27 2012-12-12 向华 Method for extracting chlorogenic acid and hyperoside from lonicera japonica leaves

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103102270A (en) * 2011-11-09 2013-05-15 安康市天源植物提取有限公司 Preparation method of chlorogenic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100554079B1 (en) * 2002-09-23 2006-02-22 학교법인 경희대학교 Lonicera japonica thunb
KR20040041235A (en) * 2002-11-09 2004-05-17 김한승 Pharmaceutical composition comprising the water-soluble component of kupferkies and the extract of crude drug effective to treat neuronal paralysis and neuralgia
KR20050005630A (en) * 2003-07-07 2005-01-14 주식회사 엠디바이오알파 Lonicera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application
KR20060008572A (en) * 2004-07-21 2006-01-27 권희정 Pharmaceutical composition comprising the extracts of ponciri fructus, lonicerae flos and angelicae dahuricae radix herb mixture for preventing and treating an articular rheumatism

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102648930A (en) * 2011-02-24 2012-08-29 北京灏銮科技发展有限公司 Microwave processing method for honeysuckle
CN102816066A (en) * 2012-08-27 2012-12-12 向华 Method for extracting chlorogenic acid and hyperoside from lonicera japonica leaves
CN102816066B (en) * 2012-08-27 2014-12-03 吉首大学 Method for extracting chlorogenic acid and hyperoside from lonicera japonica leaves

Also Published As

Publication number Publication date
KR20090089660A (en) 2009-08-24
KR101016837B1 (en) 2011-02-22
WO2009104900A3 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
US7074435B2 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
WO2012074183A1 (en) Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same
WO2018174448A1 (en) Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same
WO2012124888A2 (en) Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy
WO2016032249A1 (en) Pharmaceutical composition containing vaccinium bracteatum thunb. extract or fraction thereof as active ingredient for preventing or treating neuroinflammation or neuro-degenerative diseases
WO2009104900A2 (en) Composition comprising a flower extract of lonicera japonica thunb for preventing and treating arthritic diseases
WO2016167577A1 (en) Composition for preventing or treating inflammatory diseases or pain
WO2020256464A1 (en) Use of fraction of apios americana tuber extract having anti-inflammatory activity as preventive or therapeutic agent for alcoholic gastritis, and production method thereof
WO2009104901A2 (en) Composition comprising an extract of anemarrhena asphodeloides bunge for preventing and treating arthritic diseases
WO2015064975A1 (en) Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity
WO2017099327A1 (en) Method for alleviating osteoarthritis by using composite (p-joint 100) of achyranthes bidentata, eucommin ulmoides oliver and pomegranate extracts, which has antiinflammatory effect caused by cox2 and peg2 inhibition, cartilage protective effect caused by mmp-2 and -9 inhibition and cartilage regeneration effect caused by increase in type ii collagen synthesis
WO2017146486A1 (en) Composition for preventing or treating benign prostatic hyperplasia, containing morus alba linne extract
WO2009088264A2 (en) A composition containing arazyme for the prevention and treatment of arthritis
WO2010143825A2 (en) Anti-arthritic agent using cyathula officinalis
WO2021002642A1 (en) Composition for preventing or treating rheumatoid arthritis, comprising snake venom
WO2010090423A2 (en) Composition comprising combined crude drug extract for preventing and treating hyperlipidemia and diabetic hyperlipidemia
WO2014157811A1 (en) Composition for remedying or treating rheumatoid arthritis and osteoarthritis
WO2014157803A1 (en) Composition comprising shellfish extract as active ingredient which is for anxiety relief, improvement of convulsant, sedative action, or induction or improvement of sleep
WO2011019153A2 (en) Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient
WO2011078479A2 (en) A composition comprising the extract of prunella vulgaris l. for preventing and treating adhd disease and the use thereof
WO2014157812A1 (en) Composition for helping with joint health, or preventing, remedying, or treating rheumatoid arthritis and osteoarthritis
KR101248378B1 (en) Pharmaceutical composition for arthritis treatment and prevention
WO2019231198A1 (en) Composition comprising cimicifuga dahurica extract, fraction thereof, or cimicifuga dahurica-derived compound as effective ingredient for prevention or treatment of degenerative brain disease
KR101423316B1 (en) Composition for prevention or treatment of osteoarthritis including extracts of Phyllanthus tenellus
WO2014126269A1 (en) Pharmaceutical composition for improving male sexual function and for treating infertility

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712733

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09712733

Country of ref document: EP

Kind code of ref document: A2